Soft Tissue Sarcoma - Pipeline Review, H2 2015

Date: December 16, 2015
Pages: 470
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: S3547898099EN
Leaflet:

Download PDF Leaflet

Soft Tissue Sarcoma - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Soft Tissue Sarcoma - Pipeline Review, H2 2015’, provides an overview of the Soft Tissue Sarcoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Soft Tissue Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Soft Tissue Sarcoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Soft Tissue Sarcoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Soft Tissue Sarcoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Soft Tissue Sarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Soft Tissue Sarcoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Soft Tissue Sarcoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Soft Tissue Sarcoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Soft Tissue Sarcoma Overview
Therapeutics Development
Pipeline Products for Soft Tissue Sarcoma - Overview
Pipeline Products for Soft Tissue Sarcoma - Comparative Analysis
Soft Tissue Sarcoma - Therapeutics under Development by Companies
Soft Tissue Sarcoma - Therapeutics under Investigation by Universities/Institutes
Soft Tissue Sarcoma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Soft Tissue Sarcoma - Products under Development by Companies
Soft Tissue Sarcoma - Products under Investigation by Universities/Institutes
Soft Tissue Sarcoma - Companies Involved in Therapeutics Development
A. Menarini Industrie Farmaceutiche Riunite Srl
Advanced Proteome Therapeutics Corporation
Advenchen Laboratories, LLC
Altor BioScience Corporation
Amgen Inc.
Arog Pharmaceuticals, Inc.
Bayer AG
Bellicum Pharmaceuticals, Inc.
Boehringer Ingelheim GmbH
CASI Pharmaceuticals Inc.
Celgene Corporation
Cell Medica Limited
Cellceutix Corporation
Cellectar Biosciences, Inc.
CytRx Corporation
Daiichi Sankyo Company, Limited
Double Bond Pharmaceutical International AB
Eisai Co., Ltd.
Eli Lilly and Company
EpiZyme, Inc.
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
Gem Pharmaceuticals, LLC
GlaxoSmithKline Plc
Immune Design Corp.
Karyopharm Therapeutics, Inc.
Loxo Oncology, Inc.
Lytix Biopharma AS
MedImmune, LLC
Merck & Co., Inc.
Merrimack Pharmaceuticals, Inc.
Mirati Therapeutics Inc.
MolMed S.p.A.
Morphotek, Inc.
Northwest Biotherapeutics, Inc.
Novartis AG
Noxxon Pharma AG
OncoTherapy Science, Inc.
Onxeo SA
Pfizer Inc.
Pharma Mar, S.A.
Philogen S.p.A.
Plexxikon Inc.
Polaris Pharmaceuticals, Inc.
Recombio S.L
Rigontec GmbH
Sanofi
Shionogi & Co., Ltd.
Siena Biotech S.p.A.
Sigma-Tau S.p.A.
Sumitomo Dainippon Pharma Co., Ltd.
Targovax AS
Threshold Pharmaceuticals, Inc.
TRACON Pharmaceuticals, Inc.
Vicore Pharma AB
Soft Tissue Sarcoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
afatinib dimaleate - Drug Profile
AL-3818 - Drug Profile
aldoxorubicin hydrochloride - Drug Profile
ALT-836 - Drug Profile
APC-103 - Drug Profile
belinostat - Drug Profile
BI-853520 - Drug Profile
C-21 - Drug Profile
cabazitaxel - Drug Profile
cabozantinib s-malate - Drug Profile
cancer vaccine - Drug Profile
Cell Therapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile
Cellular Immunotherapy for GD2 Expressing Solid Tumors - Drug Profile
celyvir - Drug Profile
CMD-003 - Drug Profile
crenolanib besylate - Drug Profile
DCVax-Direct - Drug Profile
Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile
Dendritic Cells + Cytokine Induced Killer Cells - Drug Profile
DSR-6434 - Drug Profile
durvalumab + tremelimumab - Drug Profile
efatutazone - Drug Profile
emactuzumab - Drug Profile
ENMD-2076 - Drug Profile
eribulin mesylate - Drug Profile
everolimus - Drug Profile
evofosfamide - Drug Profile
Fibromun - Drug Profile
G-100 - Drug Profile
GPX-150 - Drug Profile
GSK-3174998 - Drug Profile
HDM-201 - Drug Profile
I131-CLR1404 - Drug Profile
ID-LV305 + ID-G305 - Drug Profile
ImOl-100 - Drug Profile
irinotecan hydrochloride - Drug Profile
KM-3174 - Drug Profile
KRA-0008 - Drug Profile
LK-3 - Drug Profile
LOXO-101 - Drug Profile
LTX-315 - Drug Profile
LV-305 - Drug Profile
MAT-303 - Drug Profile
mocetinostat - Drug Profile
MVXONCO-1 - Drug Profile
NGR-hTNF - Drug Profile
NOV-110501 - Drug Profile
NOXS-93 - Drug Profile
olaratumab - Drug Profile
ONCOS-102 - Drug Profile
ontuxizumab - Drug Profile
OTSA-101 - Drug Profile
paclitaxel albumin bound - Drug Profile
palbociclib - Drug Profile
panobinostat - Drug Profile
pazopanib hydrochloride - Drug Profile
pembrolizumab - Drug Profile
Peptide to Target COX-2 and MAS-GPCR for Oncology - Drug Profile
PF-03084014 - Drug Profile
PLX-7486 - Drug Profile
regorafenib - Drug Profile
ribociclib - Drug Profile
roneparstat - Drug Profile
S-588410 - Drug Profile
SA-083 - Drug Profile
sabarubicin - Drug Profile
selinexor - Drug Profile
SEN-461 - Drug Profile
talimogene laherparepvec - Drug Profile
tazemetostat - Drug Profile
TNF-PEG 20 - Drug Profile
trabectedin - Drug Profile
TRC-105 - Drug Profile
Vaccine for Soft Tissue Sarcoma - Drug Profile
vorinostat - Drug Profile
Soft Tissue Sarcoma - Recent Pipeline Updates
Soft Tissue Sarcoma - Dormant Projects
Soft Tissue Sarcoma - Discontinued Products
Soft Tissue Sarcoma - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Soft Tissue Sarcoma, H2 2015
Number of Products under Development for Soft Tissue Sarcoma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd.1)
Number of Products under Development by Companies, H2 2015 (Contd.2)
Number of Products under Development by Companies, H2 2015 (Contd.3)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd.1)
Products under Development by Companies, H2 2015 (Contd.2)
Products under Development by Companies, H2 2015 (Contd.3)
Products under Development by Companies, H2 2015 (Contd.4)
Products under Development by Companies, H2 2015 (Contd.5)
Products under Investigation by Universities/Institutes, H2 2015
Soft Tissue Sarcoma - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2015
Soft Tissue Sarcoma - Pipeline by Advanced Proteome Therapeutics Corporation, H2 2015
Soft Tissue Sarcoma - Pipeline by Advenchen Laboratories, LLC, H2 2015
Soft Tissue Sarcoma - Pipeline by Altor BioScience Corporation, H2 2015
Soft Tissue Sarcoma - Pipeline by Amgen Inc., H2 2015
Soft Tissue Sarcoma - Pipeline by Arog Pharmaceuticals, Inc., H2 2015
Soft Tissue Sarcoma - Pipeline by Bayer AG, H2 2015
Soft Tissue Sarcoma - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2015
Soft Tissue Sarcoma - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Soft Tissue Sarcoma - Pipeline by CASI Pharmaceuticals Inc., H2 2015
Soft Tissue Sarcoma - Pipeline by Celgene Corporation, H2 2015
Soft Tissue Sarcoma - Pipeline by Cell Medica Limited, H2 2015
Soft Tissue Sarcoma - Pipeline by Cellceutix Corporation, H2 2015
Soft Tissue Sarcoma - Pipeline by Cellectar Biosciences, Inc., H2 2015
Soft Tissue Sarcoma - Pipeline by CytRx Corporation, H2 2015
Soft Tissue Sarcoma - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
Soft Tissue Sarcoma - Pipeline by Double Bond Pharmaceutical International AB, H2 2015
Soft Tissue Sarcoma - Pipeline by Eisai Co., Ltd., H2 2015
Soft Tissue Sarcoma - Pipeline by Eli Lilly and Company, H2 2015
Soft Tissue Sarcoma - Pipeline by EpiZyme, Inc., H2 2015
Soft Tissue Sarcoma - Pipeline by Exelixis, Inc., H2 2015
Soft Tissue Sarcoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Soft Tissue Sarcoma - Pipeline by Gem Pharmaceuticals, LLC, H2 2015
Soft Tissue Sarcoma - Pipeline by GlaxoSmithKline Plc, H2 2015
Soft Tissue Sarcoma - Pipeline by Immune Design Corp., H2 2015
Soft Tissue Sarcoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2015
Soft Tissue Sarcoma - Pipeline by Loxo Oncology, Inc., H2 2015
Soft Tissue Sarcoma - Pipeline by Lytix Biopharma AS, H2 2015
Soft Tissue Sarcoma - Pipeline by MedImmune, LLC, H2 2015
Soft Tissue Sarcoma - Pipeline by Merck & Co., Inc., H2 2015
Soft Tissue Sarcoma - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2015
Soft Tissue Sarcoma - Pipeline by Mirati Therapeutics Inc., H2 2015
Soft Tissue Sarcoma - Pipeline by MolMed S.p.A., H2 2015
Soft Tissue Sarcoma - Pipeline by Morphotek, Inc., H2 2015
Soft Tissue Sarcoma - Pipeline by Northwest Biotherapeutics, Inc., H2 2015
Soft Tissue Sarcoma - Pipeline by Novartis AG, H2 2015
Soft Tissue Sarcoma - Pipeline by Noxxon Pharma AG, H2 2015
Soft Tissue Sarcoma - Pipeline by OncoTherapy Science, Inc., H2 2015
Soft Tissue Sarcoma - Pipeline by Onxeo SA, H2 2015
Soft Tissue Sarcoma - Pipeline by Pfizer Inc., H2 2015
Soft Tissue Sarcoma - Pipeline by Pharma Mar, S.A., H2 2015
Soft Tissue Sarcoma - Pipeline by Philogen S.p.A., H2 2015
Soft Tissue Sarcoma - Pipeline by Plexxikon Inc., H2 2015
Soft Tissue Sarcoma - Pipeline by Polaris Pharmaceuticals, Inc., H2 2015
Soft Tissue Sarcoma - Pipeline by Recombio S.L, H2 2015
Soft Tissue Sarcoma - Pipeline by Rigontec GmbH, H2 2015
Soft Tissue Sarcoma - Pipeline by Sanofi, H2 2015
Soft Tissue Sarcoma - Pipeline by Shionogi & Co., Ltd., H2 2015
Soft Tissue Sarcoma - Pipeline by Siena Biotech S.p.A., H2 2015
Soft Tissue Sarcoma - Pipeline by Sigma-Tau S.p.A., H2 2015
Soft Tissue Sarcoma - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015
Soft Tissue Sarcoma - Pipeline by Targovax AS, H2 2015
Soft Tissue Sarcoma - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015
Soft Tissue Sarcoma - Pipeline by TRACON Pharmaceuticals, Inc., H2 2015
Soft Tissue Sarcoma - Pipeline by Vicore Pharma AB, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Soft Tissue Sarcoma Therapeutics - Recent Pipeline Updates, H2 2015
Soft Tissue Sarcoma - Dormant Projects, H2 2015
Soft Tissue Sarcoma - Dormant Projects (Contd.1), H2 2015
Soft Tissue Sarcoma - Dormant Projects (Contd.2), H2 2015
Soft Tissue Sarcoma - Dormant Projects (Contd.3), H2 2015
Soft Tissue Sarcoma - Discontinued Products, H2 2015

LIST OF FIGURES

Number of Products under Development for Soft Tissue Sarcoma, H2 2015
Number of Products under Development for Soft Tissue Sarcoma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

A. Menarini Industrie Farmaceutiche Riunite Srl
Advanced Proteome Therapeutics Corporation
Advenchen Laboratories, LLC
Altor BioScience Corporation
Amgen Inc.
Arog Pharmaceuticals, Inc.
Bayer AG
Bellicum Pharmaceuticals, Inc.
Boehringer Ingelheim GmbH
CASI Pharmaceuticals Inc.
Celgene Corporation
Cell Medica Limited
Cellceutix Corporation
Cellectar Biosciences, Inc.
CytRx Corporation
Daiichi Sankyo Company, Limited
Double Bond Pharmaceutical International AB
Eisai Co., Ltd.
Eli Lilly and Company
EpiZyme, Inc.
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
Gem Pharmaceuticals, LLC
GlaxoSmithKline Plc
Immune Design Corp.
Karyopharm Therapeutics, Inc.
Loxo Oncology, Inc.
Lytix Biopharma AS
MedImmune, LLC
Merck & Co., Inc.
Merrimack Pharmaceuticals, Inc.
Mirati Therapeutics Inc.
MolMed S.p.A.
Morphotek, Inc.
Northwest Biotherapeutics, Inc.
Novartis AG
Noxxon Pharma AG
OncoTherapy Science, Inc.
Onxeo SA
Pfizer Inc.
Pharma Mar, S.A.
Philogen S.p.A.
Plexxikon Inc.
Polaris Pharmaceuticals, Inc.
Recombio S.L
Rigontec GmbH
Sanofi
Shionogi & Co., Ltd.
Siena Biotech S.p.A.
Sigma-Tau S.p.A.
Sumitomo Dainippon Pharma Co., Ltd.
Targovax AS
Threshold Pharmaceuticals, Inc.
TRACON Pharmaceuticals, Inc.
Vicore Pharma AB
Skip to top


Soft Tissue Sarcoma - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages
Soft Tissue Sarcoma - API Insights, 2015 US$ 1,250.00 Aug, 2016 · 60 pages
Ewing Sarcoma - Pipeline Review, H2 2016 US$ 2,000.00 Nov, 2016 · 210 pages
Kaposi's Sarcoma - Pipeline Review, H1 2015 US$ 1,600.00 Jan, 2015 · 31 pages

Ask Your Question

Soft Tissue Sarcoma - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: